Lawsuits Over the Price of Insulin-State Efforts for Insulin Access

Daniel G Aaron; I Glenn Cohen; Eli Y Adashi

doi:10.1001/jamainternmed.2023.6331

Lawsuits Over the Price of Insulin-State Efforts for Insulin Access

JAMA Intern Med. 2024 Jan 1;184(1):9-10. doi: 10.1001/jamainternmed.2023.6331.

Authors

Daniel G Aaron¹, I Glenn Cohen^{2

3}, Eli Y Adashi⁴

Affiliations

¹ S.J. Quinney College of Law, The University of Utah, Salt Lake City.
² Harvard Law School, Harvard University, Cambridge, Massachusetts.
³ Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard University, Cambridge, Massachusetts.
⁴ Department of Medical Science, Brown University, Providence, Rhode Island.

PMID: 38048078
DOI: 10.1001/jamainternmed.2023.6331

No abstract available

Plain language summary

This Viewpoint discusses the litigation strategy of state-initiated lawsuits alleging illegal and immoral conduct regarding the pricing of insulin by pharmaceutical companies and pharmacy benefit managers.

MeSH terms

Humans
Insulin* / therapeutic use

Substances

Insulin